SciBase receives US approval for Nevisense

29 June 2017 09:30SciBase has now received confirmation from the FDA that the Nevisense PMA has been approved. According to the letter from the FDA the device is: ‘intended for use on cutaneous lesions with one or more clinical or historical characteristics of... Read more

SciBase moves to new premises in Sundbyberg

29 June 2017 08:00SciBase has recently moved from its premises in downtown Stockholm to newly renovated premises in Sundbyberg, a part of greater Stockholm. The new address is Landsvägen 39, directly across from the Sundbyberg train station. - When it was time to... Read more

Changes to the SciBase Management team

13 June 2017 13:00- During Fredrik’s 11 years at SciBase the Company has undergone major changes from a Company with an idea in an early development phase to now having Nevisense established on a number of European markets and in the final stages... Read more

SciBase receives US patent for Nevisense electrode design

04 May 2017 08:00On May 2nd 2017 SciBase received confirmation that US patent number 9,636,035 has been approved. The patent protects the unique shape of the microneedles that enable detection of malignant melanoma in the skin using electrical impedance as demonstrated with high... Read more

SciBase publishes the Annual report for 2016

25 April 2017 08:00A pdf-version of the annual report is enclosed to this press-release. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFO Tel: +46... Read more

SciBase ships first delivery of Nevisense View

22 December 2016 10:00The new instrument Nevisense View integrates images from digital dermoscopy with Nevisense’s EIS-technology.  The result is that all information from a skin examination is gathered in the same instrument, thus improving clinic workflow. To be able to track the development... Read more

SciBase strengthens its management team with Marko Päivärinne

07 September 2016 08:00Aside from the fact that SciBase will have full control over production and thereby better conditions for making it more cost-efficient in the future, the integration of electrode manufacturing means that product development will be easier. Marko Päivärinne will be... Read more

Interim Report

13 May 2016 08:00The third quarter in figures Net sales amounted to TSEK 1,172 (1,580). The loss after tax amounted to TSEK 8,810 (12,395). The loss per share amounted to SEK 1.06 (1.50). The cash flow from current operations was negative in the amount of TSEK 9,796... Read more

Nevisense – a part of Euromelanoma

11 May 2016 09:59Eskilstuna skin clinic is one of many clinics using Nevisense during the Euromelanoma week. Nevisense is used after visual inspection by the clinician when there is uncertainty if the lesion is dangerous or not. See the video from Swedish television here Read more

SciBase publishes the Annual report for 2015

25 April 2016 08:00A pdf-version of the annual report is enclosed to this press-release. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFO Tel: +46... Read more

SciBase signs distribution agreement in Switzerland

30 March 2016 08:00Switzerland is the country in Europe with the highest prevalence of malignant melanoma. Each year approximately 2,500 new cases of the disease are diagnosed, which makes the market potentially very interesting for SciBase. Approximately 70 percent of the 500 dermatologists... Read more

Change in SciBase’s Board of Directors

02 February 2016 08:00Viktor Drvota moves on to Karolinska Development having been Head of Life Science Venture at SEB Venture Capital. Viktor has been a member of SciBase’s board since 2005. Andreas Pennervall has been an alternate director in SciBase’s board since 2013.... Read more

SciBase submits application for pre-market approval to FDA

09 December 2015 08:00“We have been working with the clinical studies and documentation that the FDA requires for several years. It has been a long process that culminated in the completion of the application during this quarter. The US market is the world’s... Read more

Interim report

12 November 2015 08:00The third quarter in figures Total net sales amounted to TSEK 995 (818). The loss after tax amounted to TSEK 10,260 (7,935). The loss per share amounted to SEK 1.24 (1.59). The cash flow from current operations was negative in the amount of... Read more

SciBase nominated for Swedish Athena Prize

10 November 2015 13:54  SciBase’s clinical study on Nevisense is one of seven finalists for the Athena Prize, the most important prize for clinical research in Sweden which is awarded on the initiative of Vinnova and Dagens Medicin. The award honors outstanding medical research with a close connection between healthcare, academia and the business world.   The winner, […] Read more

Upgraded software reduces Nevisense start-up time with up to 90%

29 October 2015 11:11SciBase has released a significant upgrade of its software for Nevisense device. The main objective of the upgrade is to streamline customers’ workflow with Nevisense by shortening the measurement start-up procedure. New in the release is that physicians no longer need to insert all patient data manually before examining suspicious lesions. Consequently, the preparation time […] Read more

SciBase among the finalists in Australian Kerrin Rennie Award

29 October 2015 11:09  The “Kerrin Rennie Award for Excellence in Medical Technology – Improving Quality of Life” is a yearly recognition by the Medical Technology Association of Australia. In this year’s award, Nevisense is one of the seven finalists.   By recognising the innovative and extraordinary contribution of medical technology in improving health outcomes for Australian patients […] Read more

Onkoderm in Stockholm

07 July 2015 11:265 questions to Onkoderm’s chairmen Uwe Reinhold and Thomas Dirschka   Onkoderm is a German network of over 50 dermatologists specialized in onco-dermatology. June 24 to 25, Chairmen Prof. Dr. Uwe Reinhold and Prof. Dr. Thomas Dirschka as well as Dr. Christina Kellner, were in Stockholm to visit Karolinska Institutet and SciBase in order to […] Read more

SciBase continues to expand in Germany and Sweden

11 June 2015 07:00- We grow at a faster rate than expected in the German market. We see both an increased demand for Nevisense and an increased test usage. To be able to manage this demand we have expanded our presence from three... Read more

Trading of SciBase on Nasdaq First North commences today

02 June 2015 07:00SciBase, a Swedish medtech company that has developed a unique instrument for the detection of malignant melanoma, announces that trading in the company’s shares on Nasdaq First North commences today with the ticker “SCIB”. The outcome of the Offering was... Read more

SciBase receives US patent approval for its micro-needle electrodes

25 May 2015 07:30SciBase’s point-of-care device Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Malignant melanoma is a fast growing type of skin... Read more


12 May 2015 09:40SciBase will be presented by CEO Simon Grant and CFO Michael Colerus at Avanza Bank’s ‘Börsdag’ at Operaterrassen in Stockholm May 20.   Programme (in Swedish) Read more

SciBase Quarterly Report

06 May 2015 09:35  ”During the first quarter of 2015, we have started to see the results of SciBase’s transformation into a more sales-focused company. Our sales have increased significantly during the first quarter and this is mainly due to a growing usage in our key market Germany. An important driver for the increased acceptance of Nevisense has been the publication of our pivotal […] Read more

Publication in British Journal of Dermatology

15 December 2014 16:21 The Nevisense pivotal study article has now been published in the BJD November 2014 issue (Volume 171, Issue 5, pages 1099–1107)   Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety British Journal of Dermatology For more information, a copy of the […] Read more

SciBase announces exclusive distribution agreement for Great Britain with Globe Skincare

03 September 2014 05:00Press Release Globe SciBase Sep 2014SciBase, a leader in skin cancer detection technology with its unique point-of-care device Nevisense, today announced that it has entered into an exclusive agreement with Globe Skincare Ltd to distribute Nevisense in Great Britain. UK-based Globe Skincare is a leading distributor of skin care and analysis products to the dermatological […] Read more

Nevisense in Media

09 July 2014 09:50Links to recent media posts on Nevisense: Swedish News in English: The Local 2014-07-08 Swedish Media: SvD 2014-07-08 Dagens Nyheter 2014-07-08 Dagens Industri 2014-07-08 Aftonbladet 2014-07-08 Expressen 2014-07-08 Sydsvenskan 2014-07-08 Göteborgsposten 2014-07-08 Helsingborgs Dagblad 2014-07-08 Östgöta Correspondenten 2014-07-08 Uppsala Nya Tidning 2014-07-08 Borås Tidning 2014-07-08 Norrköpings Tidningar 2014-07-08 Barometern (Oskarshamn) 2014-07-08 Västerbottens-Kuriren 2014-07-08 Skaraborgs Läns […] Read more

Publication in British Journal of Dermatology validates the breakthrough Nevisense system as an accurate device for melanoma detection

03 June 2014 04:05SciBase AB, a leader in skin cancer detection technology, today announced the British Journal of Dermatology publication of a multi-centre international study for its unique point-of-care device, Nevisense. The results from the world’s largest study of its kind show that Nevisense provides an accurate and important new tool for the detection of malignant melanoma, the […] Read more

New Nevisense Software Release Available

16 May 2014 14:02New Nevisense Software Release SW VER 5.7 Available This release contains improvements and new features: Possibility to customise date and time format Improved Nevisense report To order the upgrade kit (article number 142-0001) e-mail or contact your sales representative. Read more

SciBase announces new CEO

30 April 2014 12:59Simon Grant appointed as CEO of SciBase. SciBase today announced that its Board of Directors has, effective as per April 28th 2014, appointed Simon Grant as Chief Executive Officer to take the next step in the development of the company. Simon Grant replaces Anders Lundqvist who has served as CEO of SciBase since 2007. Simon brings […] Read more

SciBase announces distribution agreement with Lischke Medizintechnik in Germany

13 January 2014 07:00SciBase, a leader in skin cancer detection technology, announced today that it has entered into a distribution agreement with Lischke Medizintechnik for distribution of Nevisense electrode disposable components in Germany. Nevisense is a point of care device used to support clinicians to accurately detect malignant melanoma. A disposable component is used in combination with the […] Read more

SciBase raises SEK 120 million ($18 million)

17 December 2013 12:46SciBase has recently closed a financing round of SEK 120 million ($18 million), to be divided in two tranches. The funds will finance the company through the ongoing market introduction in Europe/Australia as well as the regulatory approval process and subsequent launch in the US. The financing round was secured in a combination of current […] Read more

Nevisense gains Australian approval

09 October 2013 10:39SciBase has received clearance from the Thereapeutic Goods Administration (TGA) to commercialise Nevisense in Australia. Nevisense will be marketed in Australia and New Zealand by Equipmed, a leading independent distributor of devices in dermatology in the region. Read more

SciBase announces exclusive distribution agreement with Equipmed for Australia and New Zealand

20 June 2013 04:00SciBase, a Swedish company introducing a break-through product, Nevisense, for skin cancer detection, announced today that it has entered into an exclusive agreement with Equipmed to distribute Nevisense in Australia and New Zealand. Equipmed is a successful distributor of equipment within dermatology in Australia and New Zealand, says Anders Lundqvist, CEO of SciBase. Equipmed has […] Read more

SciBase Announces Positive Top-Line Results from Pivotal Study

01 August 2012 14:00Excellent clinical study results for SciBase’s unique product Nevisense in the largest prospective study ever conducted in the detection of Malignant Melanoma. The Swedish medtech company, SciBase, today announced top-line results of its pivotal study SIMPS of Nevisense, a unique non-invasive point-of-care device for detection of Malignant Melanoma, the deadliest form of skin cancer. 22 […] Read more

SciBase is presented with the 2011 Frost & Sullivan Europe Technology Innovation Award in Skin Cancer Diagnostics

24 August 2011 14:31The 2011 Frost & Sullivan Europe Technology Innovation Award in Skin Cancer Diagnosis is presented to SciBase AB in recognition of the company’s pioneering development of a unique electrical impedance spectroscopy (EIS) technology for the detection of malignant melanoma. See Frost & Sullivan press release and analyst report below. For more information, please contact: 
Anders […] Read more

SciBase at the 13th Annual BIO CEO & Investor Conference, New York

25 January 2011 14:36SciBase will present at the upcoming BIO CEO & Investor Conference in New York, USA. The conference takes place at the Waldorf Astoria New York Hotel, February 14-15, 2011. Anders Lundqvist, President & CEO, is scheduled to present on February 15, 2011 at 3.00 PM. For more information, please contact: 
Anders Lundqvist, CEO SciBase AB, […] Read more

SciBase successfully achieves clinical study objectives

30 August 2010 14:38Study targets met with SciBase unique method for first line detection of Malignant Melanoma Swedish medtech company SciBase is in the final stage of development with its unique method for first line detection of malignant melanoma. A clinical study has recently been completed involving 1200 patients and 200 malignant melanomas from 19 clinical centers in […] Read more

SciBase AB has initiated its pivotal study for final clinical verification

22 March 2010 14:57The pivotal study will be performed at 23 clinical institutions in Europe and the US, and will be the final clinical verification of the methods accuracy. When the pivotal study is finalized and the results are made available, market introduction in Europe and Australia is to be initiated, which is expected during 2011. The study data […] Read more

SciBase receives IDE approval from FDA

23 October 2009 14:59SciBase has received IDE approval from FDA for the pivotal study that will be performed in 2010 to create scientific evidence about the methods accuracy. The IDE (investigational Device Exemption) approval allows SciBase to perform the clinical study in Europe and the US at up to 25 clinical institutions. Please read the attached press release for more information: […] Read more

SciBase reinforces the management team

08 January 2008 15:01SciBase has over the last months reinforced the management team with the aim to build necessary competencies and resources for the continued development of the company. Gun-Britt Personne has joined SciBase as Chief Financial Officer. Gun-Britt Personne has more than 25 years of financial and management experience from various leading positions within the Pharmacia Group. She […] Read more

Change of Management at SciBase AB

01 May 2007 15:04As SciBase is approaching the commercial phase Christer Wallin steps down as CEO at SciBase AB. The Board of Directors appoints Anders Lundqvist as new CEO from May 1, 2007. Christer Wallin joined the company in 2004. During his time, major steps and significant progress has been made in the development of the company and […] Read more

SciBase moves to new bigger facility

27 April 2007 15:05After 16 months, SciBase is moving from its current location at Sveavägen 25 to a new bigger facility at Kammakargatan 22 in Stockholm. SciBase will be working out of the new facility from the 2nd of May. The new facility is twice the size of the existing, and will allow SciBase to continue with its rapid development of […] Read more

SciBase expands the IMATS study

08 January 2007 15:07SciBase expands the ongoing IMATS (International Melanoma Algorithm Training Study) studywith additional clinical sites in England and in Sweden. This allows the multi-center IMATS study to be conducted in parallel at 12 sites in Germany, Sweden,
Czech Republic, Hungary and the UK.
SciBase receives extensive and valuable clinical data in the IMATS study from a long range […] Read more

SciBase strengthens its management team

19 December 2006 15:09SciBase AB has over the last months continued to broaden its management team with four key appointments in business development, regulatory affairs, production/logistics and in clinical research. The recent recruitments has been made to strengthen SciBase’s organization for the continued growth of the company and establishing the infrastructure and operational excellence needed to bring the […] Read more

SciBase to present at “Riksstämman” – the annual general meeting of the Swedish Society of Medicine on the 30th of November 2006

28 November 2006 15:10The SciBase method and the research behind the method will be presented at “Riksstämman” – the annual general meeting of the Swedish Society of Medicine on the 30th of November 2006. The presentation “Shedding light on dark lesions using electronic biopsy” will be held in one of the scientific symposias covering Dermatology & venereology. (Room: […] Read more

Investor, SEB and CapMan invest 100 MSEK in SciBase AB

21 June 2006 15:44The investment means that Investor Growth Capital together with SciBase’s current owners SEB Företagsinvest and Capman controls 80 percent of the Swedish medical technology company. The investment is done as a new share issue. SciBase’s goal is to become a world leader in the early discovery of skin cancer. “Getting the Investor Growth Capital as […] Read more

The IMATS study

14 June 2006 15:44A clinical study, the IMATS (International Melanoma Algorithm Training study) is ongoing – it is a comprehensive clinical study taking place at nine clinics in four countries: Sweden, Germany, Hungary and the Czech Republic. The purpose of the IMATS is to collect data to further refine the SciBase method. Read more

Investment Event

13 June 2006 15:46SciBase is presenting at SIE (Scandinavian Investment Event) at Boston Scientific Corporation, June 14th. The goal of this event is to connect Scandinavian med-tech companies with the US industry and financial partners. Read more